Du Toit, George creator Autor Lack, Gideon text pe monographic spa eng

print

páginas: 2449-2458 Early introduction of peanut protein reduces allergy prevalence by approximately 80%, with efficacy diminishing as introduction is delayed. Appropriate prevention involves ingestion of approximately 2 g of peanut protein weekly for infants at low risk and 4 to 6 g weekly for infants at high risk. Population-level implementation that targets all infants achieves greater reduction in disease burden than approaches that target only high-risk groups, although disparities exist among some ethnic groups and groups with restricted access to care. Peanut immunotherapy initiated in younger children (1 to 3 years of age) shows superior efficacy and higher rates of clinical remission as compared with immunotherapy initiated in older children. The natural history of untreated peanut allergy follows a trajectory of increasing peanut-specific IgE levels and clinical reactivity over time, underscoring the importance of early intervention during this narrow developmental window. ALERGIA DERMATOLOGÍA MEDICINA CLINICA ENFERMEDADES INFANTILES NUTRICIÓN Massachusetts NEJM Group NEJM006 0028-4793 ESSALUD BMG 20260805002026.0 ESSALUD